Acurx Pharmaceuticals

Q2 FY2026 EarningsQ2 FY26 missed consensus estimates on the bottom line despite zero revenue being in-line with expectations. Net loss (GAAP) was $2.25M vs. $1.90M expected, resulting in an EPS (GAAP) of -$0.53, missing the -$0.34 consensus. Research and Development expenses surged 104% YoY to $1.07M due to the new recurrent CDI trial program. While financing activities raised $6.2M in the first half of the year, the current cash balance of $10.7M is deemed insufficient for the next 12 months, leading to a going concern warning.